(REVB) Revelation Biosciences, Inc. Business Model Canvas Research

Revelation Biosciences, Inc. must work with regulators and ethics committees through FDA-facing review and IRB oversight before human studies can start. This 2-step gate protects patients, can slow trial timing, and also shapes label strategy because the FDA and IRB both influence what can be tested, when, and how.

• FDA review: trial authorization
• IRB oversight: patient protection
• 2 approval layers can delay timelines
• Review scope can shape label strategy

Revelation Biosciences, Inc. relies on public-market investors and financing partners to fund clinical development, day-to-day operations, and SEC reporting. As a pre-commercial biotech with no marketed products, it needs outside capital to keep trials moving and to cover public-company costs.

• Public equity funds R&D and compliance
• Debt or PIPE capital supports trial spend
• No product sales means cash burn matters

Revelation Biosciences, Inc. centers regulatory and quality execution on FDA submissions, safety updates, and trial records, while keeping clinical and manufacturing work in compliance. For a San Diego-based public biotech in development mode, this is a core activity that protects program timing, data integrity, and investor trust.

• Prepare filings and safety updates
• Track trial documents and controls
• Keep clinical and GMP compliance

For Revelation Biosciences, Inc., intellectual property management protects pipeline assets, methods, and know-how, and it helps preserve freedom to operate as the Company moves from research to trials and partner talks. It also supports future licensing and commercialization by making the asset package easier to diligence and value.

• Protects core pipeline assets and know-how
• Supports freedom to operate
• Strengthens partnering and licensing value

Clinical and regulatory data at Revelation Biosciences, Inc. comes from development work and trial execution, and it is the core evidence used to show safety, efficacy, and fit with partners. It gains value as each program advances and as the company adds new study readouts, protocol data, and regulatory filings.

• Built from trials and development work
• Supports safety and efficacy claims
• Helps partnering and licensing talks
• Becomes more valuable as programs advance

Revelation Biosciences, Inc. was founded in 2019 and renamed in January 2022; its San Diego, California base helps it tap one of the U.S. biotech talent hubs, while public-company status gives it a route to equity funding through listed-market capital raises.

• Founded 2019; renamed January 2022
• San Diego supports biotech hiring
• Public listing supports equity access

Revelation Biosciences, Inc.’s CKD prevention and treatment angle fits a long care path in a market where chronic kidney disease affects about 850 million people worldwide and roughly 37 million U.S. adults. By targeting both prevention and therapy, it can reach earlier-stage patients and advanced cases, which helps widen the total addressable kidney market.

• Broadens reach across CKD stages
• Targets prevention and treatment demand
• Backs a large, growing patient pool

Revelation Biosciences, Inc.’s therapeutics-plus-diagnostics scope can support both treatment and test products, which broadens the revenue path and makes partnering easier. As a pre-revenue company with FY2025 product revenue of $0, the model fits companion-diagnostic and platform-style value creation, where one program can feed multiple shots at monetization.

• Therapy and test revenue lanes
• Stronger partner appeal
• Companion-diagnostic upside

Partnering outreach at Revelation Biosciences, Inc. is built to win potential licensees and strategic collaborators with data packages and milestone proof, before any commercial scale-up. As a pre-revenue biotech, this relationship path matters because partner interest usually follows clinical readouts, not sales.

• Data packages drive partner talks
• Milestones shape licensing terms
• Best used before scale-up

Revelation Biosciences, Inc.'s medical-scientific credibility rests on evidence generation and publication-quality data, which matter in kidney care where chronic kidney disease affects about 14% of adults worldwide. Strong clinical data helps build trust with clinicians and partners, and can support future adoption if the science shows clear, reproducible renal benefit.

• Evidence first, trust follows.
• Publication-grade data supports adoption.
• Kidney care needs clean clinical proof.

Scientific conferences are a key channel for Revelation Biosciences, Inc. to reach clinicians, researchers, and partners in kidney disease and immunology, before any commercial launch. Congresses like KDIGO and major immunology meetings can draw thousands of attendees, so one poster or talk can build early credibility fast.

• Targets clinical and research buyers
• Fits kidney and immunology focus
• Builds pre-launch awareness

Business development meetings at Revelation Biosciences, Inc. are the main channel for licensing and collaboration talks, turning clinical readouts into partner interest and future deal terms. They matter most when the company needs non-dilutive funding and pipeline monetization, since 2025 share count was about 4.7 million and the market cap stayed micro-cap sized.

• License and co-dev talks
• Convert data to partner demand
• Support pipeline monetization

Diagnostic laboratories are the first likely users of Revelation Biosciences, Inc.'s immune-targeted tests because they need validated assays, clear cutoffs, and workflows that fit high-throughput platforms. This segment matters most if commercialization reaches regulated lab use in 2026, when adoption depends on turnaround time, reproducibility, and reimbursement.

• Need validated, lab-ready assays
• Fit existing workflow and throughput
• Adoption hinges on commercialization

Strategic biotech and pharma partners are likely Revelation Biosciences, Inc.’s best route to scale platform assets beyond its own capital. These potential licensees can fund development in exchange for program rights, which lowers dilution and speeds validation if the data support a deal.

• License programs or platform assets

• Co-fund trials for rights

• Extend reach beyond internal cash

For Revelation Biosciences, Inc., regulatory, legal, and IP spend covers SEC filings, FDA compliance, patent filings, and outside counsel, a must for any public biopharma in a regulated market. These costs protect value before revenue, and patent upkeep can rise to $7,400 per U.S. patent by year 11, before legal defense and filing fees.

• SEC, FDA, and Nasdaq compliance
• Patent filing and maintenance fees
• Outside counsel and IP defense

G&A and public-company costs at Revelation Biosciences, Inc. cover payroll, SEC reporting, audit, and office overhead, and they stay fixed even when R&D slows. Founded in 2019 and renamed in 2022 as a public entity, the Company must fund these day-to-day costs to keep filings, controls, and governance running.

• Payroll and office overhead
• SEC reporting and audit
• Public-company compliance costs

Revelation Biosciences, Inc. can use collaboration funding to offset research and development spend by having partners cover part of trial work, which is especially useful when two lead programs need capital at the same time. This revenue stream can reduce burn, limit dilution, and keep both programs moving without funding all development internally.

• Partner-funded R&D support
• Shares trial and development costs
• Fits two lead programs

Future product sales could become Revelation Biosciences, Inc.’s main long-term revenue source if an approved therapeutic or diagnostic reaches market, but this stream is still unrealized because the Company remains in clinical development. Revenue depends on regulatory clearance, launch timing, and commercial uptake, so today it is still pre-revenue from products.

• Long-term sales need FDA success.
• No product revenue yet.
• Commercialization drives future cash flow.